Checchi Capital Advisers LLC Has $402,000 Stock Holdings in GSK plc (NYSE:GSK)

Checchi Capital Advisers LLC boosted its position in shares of GSK plc (NYSE:GSK) by 3.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,885 shares of the pharmaceutical company’s stock after acquiring an additional 440 shares during the period. Checchi Capital Advisers LLC’s holdings in GSK were worth $402,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its position in shares of GSK by 40.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 11,764 shares of the pharmaceutical company’s stock valued at $481,000 after purchasing an additional 3,405 shares during the period. Pinnacle Associates Ltd. boosted its stake in GSK by 6.2% during the third quarter. Pinnacle Associates Ltd. now owns 32,921 shares of the pharmaceutical company’s stock worth $1,346,000 after buying an additional 1,912 shares in the last quarter. JFS Wealth Advisors LLC increased its holdings in GSK by 1,429.4% in the 3rd quarter. JFS Wealth Advisors LLC now owns 29,426 shares of the pharmaceutical company’s stock valued at $1,203,000 after buying an additional 27,502 shares during the period. US Bancorp DE raised its stake in shares of GSK by 12.2% in the 3rd quarter. US Bancorp DE now owns 236,770 shares of the pharmaceutical company’s stock valued at $9,679,000 after buying an additional 25,781 shares in the last quarter. Finally, Lincluden Management Ltd. boosted its position in shares of GSK by 1.3% during the 3rd quarter. Lincluden Management Ltd. now owns 66,001 shares of the pharmaceutical company’s stock valued at $2,698,000 after acquiring an additional 833 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Down 0.2 %

GSK stock opened at $37.33 on Friday. The business has a fifty day moving average price of $34.91 and a 200 day moving average price of $37.30. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The stock has a market capitalization of $77.36 billion, a price-to-earnings ratio of 23.47, a P/E/G ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.21%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is presently 98.74%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on GSK. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.